However, a comprehensive analysis by Schmalbrock et al. investigating genetic causes for midostaurin resistance in FLT3-ITD-mutated AML demonstrated that secondary FLT3-ITD mutations occurred in only 11% of patients at the time of r/r disease. The gene discussed is FLT3; the disease is acute myeloid leukemia.